Skeletal muscle loss and body composition in progressive supranuclear palsy: A retrospective cross-sectional study

Yasuyuki Takamatsu; Ikuko Aiba

doi:10.1371/journal.pone.0253079

Peer Review History

Original SubmissionJanuary 26, 2021
16 Apr 2021 Decision Letter - Ezio Lanza, Editor PONE-D-21-02875 Skeletal muscle loss and body composition in progressive supranuclear palsy: A retrospective cross-sectional study PLOS ONE Dear Dr. Aiba, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Apr 30 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Ezio Lanza, M.D. Academic Editor PLOS ONE Additional Editor Comments : Please consider citing in the introduction the following article, published by PLOS ONE, regarding the use of sarcopenia as predictor of survival also in the setting of cancer https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0232371 Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating the following in the Competing Interests section: "I.A. serves as a consultant for Biogen MA Inc. and AbbVie GK." Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf. Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests 3. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 2 in your text; if accepted, production will need this reference to link the reader to the Table. Reviewers' comments: Reviewer's Responses to Questions 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: I thank the authors for taking consideration of the relation between body composition parts and PSP patients. In order for the manuscript to be scientifically valid regarding the association suggested, I suggest that adjustment for other confounders causing wasting and sarcopenia should be mentioned in the manuscript [exercise state of the patient versus controls, the caloric pattern [moderate, mild or high according to daily activity and occupation], details of ergogenic or ergopenic medications and nutritional state including the presence or absence of bulbar dysfunction or anorexia]. These factors should be elucidated in my experience in order to make the publication worthy of targeting the association between PSP and sarcopenia. Reviewer #2: Manuscript by Takamatsu and Aiba is the first to report skeletal muscle loss in progressive supra nuclear palsy (PSP). Small size of studied groups of patients and controls is a significant limitation. However comparative analyses performed by sex, identified significant decrease in SMI in PSP groups driven by leg SMI. This paper should be of interest in the field of clinical PSP. [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. https://doi.org/10.1371/journal.pone.0253079.r001
Revision 1
22 Apr 2021 Author Response To editor and reviewers We thank the editor and reviewers for taking the time to review our manuscript. We have revised the manuscript according to the editor’s and reviewers’ comments. The revised portions of the manuscript are highlighted in red. Additional Editor Comments: Please consider citing in the introduction the following article, published by PLOS ONE, regarding the use of sarcopenia as predictor of survival also in the setting of cancer https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0232371 Following the editor’s suggestion, we cited the following article in the introduction: Lanza E et al. Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma. PLoS One. 2020. Introduction: page 3, lines 44-45. Sarcopenia has been associated with motor functional disability, lower quality of life (QOL), and mortality [2–4]. References: page 11, lines 233-236. 4. Lanza E, Masetti C, Messana G, Muglia R, Pugliese N, Ceriani R, et al. Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma. PLoS One. 2020;15: 1–12. doi:10.1371/journal.pone.0232371 Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. We confirmed our reference list to be complete and correct. When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf Following the journal requirements, we revised the formatting of our manuscript based on these sample PDFs. 2. Thank you for stating the following in the Competing Interests section: "I.A. serves as a consultant for Biogen MA Inc. and AbbVie GK." Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf. Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests Yes, we agree with the PLOS ONE policies on sharing data and materials. We mentioned about COI in cover letter. 3. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 2 in your text; if accepted, production will need this reference to link the reader to the Table. Following the journal requirements, we revised the manuscript. Results: page 7, line 144. In the entire PSP group, there was no significant correlation between SMI on one hand and disease duration, mRS and BI on the other (Table 2). Reviewers' comments: Reviewer #1: I thank the authors for taking consideration of the relation between body composition parts and PSP patients. In order for the manuscript to be scientifically valid regarding the association suggested, I suggest that adjustment for other confounders causing wasting and sarcopenia should be mentioned in the manuscript [exercise state of the patient versus controls, the caloric pattern [moderate, mild or high according to daily activity and occupation], details of ergogenic or ergopenic medications and nutritional state including the presence or absence of bulbar dysfunction or anorexia]. These factors should be elucidated in my experience in order to make the publication worthy of targeting the association between PSP and sarcopenia. Thank you for raising very important points. The remark about confounders causing sarcopenia is critical and the lack of data was a significant limitation in this study. Therefore, following the reviewer’s comment, we revised the manuscript and added some references. Discussion: page 9, lines 185-189. The second limitation was that this study was lack of data about related factors and confounders causing skeletal muscle mass loss or sarcopenia, such as motor function (e.g., muscle strength, gait speed) [1,15], daily physical activity (e.g., exercise state) [20,21], nutrition sate (e.g., caloric pattern, intake of ergogenic or ergogenic drugs, bulbar dysfunction, anorexia) [22–25]. References: page 13, line 294 – page 14, line 312. 20. Steffl M, Bohannon R w, Sontakova L, Tufano JJ, Shiells K, Holmerova I. Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging. 2017;Volume 12: 835–845. doi:10.2147/CIA.S132940 21. Lee SY, Tung HH, Liu CY, Chen LK. Physical Activity and Sarcopenia in the Geriatric Population: A Systematic Review. J Am Med Dir Assoc. 2018;19: 378–383. doi:10.1016/j.jamda.2018.02.003 22. Naseeb MA, Volpe SL. Protein and exercise in the prevention of sarcopenia and aging. Nutr Res. 2017;40: 1–20. doi:10.1016/j.nutres.2017.01.001 23. Cruz-Jentoft AJ, Kiesswetter E, Drey M, Sieber CC. Nutrition, frailty, and sarcopenia. Aging Clin Exp Res. 2017;29: 43–48. doi:10.1007/s40520-016-0709-0 24. Azzolino D, Damanti S, Bertagnoli L, Lucchi T, Cesari M. Sarcopenia and swallowing disorders in older people. Aging Clin Exp Res. 2019;31: 799–805. doi:10.1007/s40520-019-01128-3 25. Zhao WT, Yang M, Wu HM, Yang L, Zhang X mei, Huang Y. Systematic Review and Meta-Analysis of the Association Between Sarcopenia and Dysphagia. J Nutr Heal Aging. 2018;22: 1003–1009. doi:10.1007/s12603-018-1055-z Reviewer #2: Manuscript by Takamatsu and Aiba is the first to report skeletal muscle loss in progressive supra nuclear palsy (PSP). Small size of studied groups of patients and controls is a significant limitation. However comparative analyses performed by sex, identified significant decrease in SMI in PSP groups driven by leg SMI. This paper should be of interest in the field of clinical PSP. Thank you for reviewing our manuscript and being interest. We would like to increase the sample size and proceed with further verification. Attachments Attachment Submitted filename: Responce_to_Reviews_Takamatsu and Aiba_Plos One_21Apr2021.docx https://doi.org/10.1371/journal.pone.0253079.r002
28 May 2021 Decision Letter - Ezio Lanza, Editor Skeletal muscle loss and body composition in progressive supranuclear palsy: A retrospective cross-sectional study PONE-D-21-02875R1 Dear Dr. Aiba, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Ezio Lanza, M.D. Academic Editor PLOS ONE Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed https://doi.org/10.1371/journal.pone.0253079.r003
Formally Accepted
2 Jun 2021 Acceptance Letter - Ezio Lanza, Editor PONE-D-21-02875R1 Skeletal muscle loss and body composition in progressive supranuclear palsy: A retrospective cross-sectional study Dear Dr. Aiba: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Ezio Lanza Academic Editor PLOS ONE https://doi.org/10.1371/journal.pone.0253079.r004

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .